NCT04590417View on ClinicalTrials.gov

Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

October 1, 2025

Conditions
Drug Interaction
Interventions
DRUG

Estradiol valerate 2 mg, cyproterone acetate 25 mg

The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.

Trial Locations (1)

10330

Institute of HIV Research and Innovation (IHRI), Bangkok

All Listed Sponsors
lead

Thai Red Cross AIDS Research Centre

OTHER

NCT04590417 - Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women | Biotech Hunter | Biotech Hunter